Quarterly ResultApr 30, 2026, 04:15 PM
ARDX Q1 Revenue +27.5% to $94.5M; Net Loss Narrows to $37.6M
AI Summary
ARDX reported a 27.5% increase in total revenues to $94.5 million for Q1 2026, with net loss narrowing to $37.6 million from $41.1 million year-over-year. IBSRELA sales surged by 57.8% to $70.1 million, while XPHOZAH sales remained flat at $23.3 million, impacted by its inclusion in the ESRD PPS. The company also announced the first commercial sales of tenapanor in China by Fosun Pharma and the termination of its Canadian license agreement with Knight.
Key Highlights
- Total revenues increased 27.5% to $94.5 million in Q1 2026 from $74.1 million in Q1 2025.
- Net loss narrowed to $37.6 million ($0.15/share) in Q1 2026 from $41.1 million ($0.17/share) in Q1 2025.
- IBSRELA net product sales grew 57.8% to $70.1 million in Q1 2026.
- XPHOZAH net product sales were $23.3 million in Q1 2026, flat year-over-year, impacted by ESRD PPS.
- Fosun Pharma reported first commercial sales of tenapanor in China in March 2026.
- Terminated exclusive license agreement with Knight for tenapanor in Canada effective March 13, 2026.
- Net cash used in operating activities improved to $32.2 million from $38.5 million year-over-year.
- Cash and cash equivalents decreased to $31.2 million from $68.0 million since December 31, 2025.